TG账号秒盗免杀破解技术|【唯一TG:@heimifeng8】|飞机盗号软件VIP破解技术✨谷歌搜索留痕排名,史上最强SEO技术,20年谷歌SEO经验大佬✨BMJ: Annual Blood Test May Help Detect Multiple Cancers at an Early Stage
A single blood test designed to detect chemical signals indicating the presence of various types of cancer could potentially prevent disease progression to a late stage while the malignant tumor is still in its early phase and treatable in approximately half of cases, according to a modeling study published in The BMJ.
As such, implementing this test—officially known as the «multi-cancer early detection (MCED) test»—on an annual or biennial basis could improve treatment outcomes by preventing disease advancement, researchers suggest. Currently, only a few types of cancer can be reliably diagnosed—namely breast, bowel, cervical, and lung cancer in high-risk groups.
Researchers note that while such screenings are effective in reducing mortality from these cancers, they can also lead to false positives and overdiagnosis. The optimal interval at which screening can detect most cancers at early stages (I and II) while minimizing unnecessary testing and treatment is still unclear.
To gain insight into the potential of future clinical applications, the scientists used a previously published disease progression model for various cancers. They applied it to predict the impact of regular MCED screening on the timing of cancer diagnosis and patient mortality under different screening schedules in individuals aged 50–79 receiving standard medical care.
The modeled screening intervals ranged from every 6 months to every 3 years, with a focus on annual and biennial screening across two cancer development scenarios:
A slow progression, where tumors remain at stage I for 2 to 4 years before advancing;
And a “fast aggressive” progression, where tumors stay at stage I for only 1 to 2 years before progressing more rapidly.
The study included a broad range of cancers, such as anal, bladder, breast, cervical, colorectal, esophageal, gallbladder, head and neck, kidney, liver/biliary tract, lung, ovarian, pancreatic, prostate, sarcoma (soft tissue/bone), stomach, thyroid, urothelial, and uterine cancers, as well as leukemia, lymphoma, melanoma, and hematological malignancies (myeloid neoplasms, immune cell cancers like plasma cell neoplasms).
Annual MCED screening under the fast-tumor-growth scenario was associated with a significantly higher number of diagnoses: 370 more cancer signals detected per 100,000 people screened annually, 49% fewer late-stage diagnoses, and 21% fewer deaths over five years compared to standard care.